Physician profile
Farzin Sehati
NPI 1477636389
$1,174.80
in general payments reported to CMS, 2019-2025
11 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $125 · 2022: $287 · 2023: $201 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $393.66 | 2022-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Abbott Laboratories | $149.95 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $125.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $121.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.89 | 2019 | |
| Ardelyx, INC. | $112.44 | 2022-2023 | Ibsrela |
| Neurocrine Biosciences, INC. | $49.30 | 2022 | |
| Redhill Biopharma INC. | $38.12 | 2022 | |
| Glaxosmithkline, LLC. | $25.46 | 2023 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $20.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzin Sehati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.